03 Jan2019

SQZ Biotech Strengthens Leadership Team with Appointment of Chief Medical Officer

Written by 2020HCP.com. Posted in News

Industry veteran, Oliver Rosen, MD, to join executive team as SQZ prepares to enter the clinic WATERTOWN, Mass., Jan. 3, 2019 –- SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the appointment of Oliver Rosen, MD, as Chief Medical Officer. Dr. Rosen will oversee the clinical development of SQZ’s cell therapy pipeline and joins the company as it prepares to enter the clinic with a lead oncology candidate.
15 Oct2018

SQZ Biotech Expands Cell Therapy Partnership with Roche to Develop Antigen Presenting Cells for Immune-Oncology

Written by 2020HCP.com. Posted in News

  • Collaboration combines SQZ Biotech’s novel cell therapy platform with Roche´s cancer immunotherapy expertise 
  • SQZ to receive up to $125 million in upfront and near-term milestone payments
October 15, 2018 – Watertown, MA – SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the expansion of its collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) in cellular therapy. The expanded partnership furthers the synergistic combination of SQZ’s innovation and expertise in cell therapy with Roche’s cancer immunotherapy expertise. Under the terms, SQZ and Roche will jointly develop and commercialize certain products based on antigen presenting cells (APCs) created by the SQZ platform for the treatment of oncology indications.
16 Nov2017

New Peer-to-Peer Feedback Drives Employee Engagement to Improve Work Quality

Written by 2020HCP.com. Posted in News

EightSpokes launches first real-time feedback loop technology to address persistent business challenge of low employee engagement while enabling ongoing work improvement

CAMBRIDGE, MA – November 16, 2017 – EightSpokes introduces Peer-to-Peer (P2P) Feedback™ with its latest release of Enlighten, the world’s first cloud-based Enterprise Project Collaboration (EPC) solution. It enables real-time feedback from colleagues collaborating on a project – from drug development to commercialization. With P2P Feedback, users can ensure that every assignment achieves its intended outcome and that team members receive timely and relevant feedback to course-correct as needed, while it still matters. It also naturally propels organizations to continuously improve performance, ultimately ratcheting employee engagement enterprise-wide.   READ MORE
22 Oct2015

VBL Therapeutics Presents Positive Data on VB-111 in Advanced Radioactive Iodine Refractory Differentiated Thyroid Cancer at the ITC 2015 Conference

Written by 2020HCP.com. Posted in News

Multi-Cohort Phase 2 Trial Met Its Primary Endpoint of 6-Month PFS
TEL AVIV, Israel, Oct. 21, 2015 (GLOBE NEWSWIRE) — VBL Therapeutics (NASDAQ:VBLT), today announced positive results from its multi-cohort Phase 2 trial of VB-111 in advanced radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). The pre-specified primary trial endpoint of 6-month Progression Free Survival (PFS) for at least 25% of enrolled patients was met, showing a dose response for VB-111. In the trial, which was conducted at the Mayo Clinic and Massachusetts General Hospital, VB-111 also demonstrated favorable safety and survival data, and a potential for dose-dependent disease stabilization. The results were presented today at the 15th International Thyroid Congress held in Orlando, FL.

Latest News